Replies to post #2910 on Revance Therapeutics Inc (RVNC)

[marthambles]

Then again, a footnote in their investor section stated that "at least 50% of patients treated with Daxxify in Sakura 1 and Sakura 2 had none or mild frown lines . . . for 24 and 23.9 weeks or longer."

I am a bit confused.

[DewDiligence]

No, all of the discussion in question concerns median values (not mean values).